Leerink Partnrs Decreases Earnings Estimates for AnaptysBio

Key Points

• Leerink Partners has lowered its Q3 2025 EPS estimate for AnaptysBio to (0.85), slightly down from a previous estimate of (0.84).
• The consensus estimate for AnaptysBio’s current full-year earnings is (6.08) per share, reflecting ongoing challenges for the biotechnology firm.
• The stock has been rated with a Moderate Buy consensus and has a current average price target of $48.75.

AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Equities research analysts at Leerink Partnrs dropped their Q3 2025 EPS estimates for shares of AnaptysBio in a report issued on Tuesday, September 30th. Leerink Partnrs analyst D. Risinger now forecasts that the biotechnology company will post earnings per share of ($0.85) for the quarter, down from their prior forecast of ($0.84). The consensus estimate for AnaptysBio's current full-year earnings is ($6.08) per share. Leerink Partnrs also issued estimates for AnaptysBio's Q4 2025 earnings at $1.04 EPS, FY2025 earnings at ($1.69) EPS, FY2026 earnings at ($2.98) EPS, FY2027 earnings at ($3.01) EPS, FY2028 earnings at ($1.87) EPS and FY2029 earnings at ($0.82) EPS.

A number of other equities research analysts have also recently weighed in on the company. Wedbush restated an "outperform" rating and issued a $45.00 price target on shares of AnaptysBio in a research note on Tuesday. JPMorgan Chase & Co. lifted their target price on shares of AnaptysBio from $42.00 to $80.00 and gave the stock an "overweight" rating in a report on Thursday, July 24th. HC Wainwright raised their price objective on shares of AnaptysBio from $38.00 to $59.00 and gave the stock a "buy" rating in a research report on Tuesday. Finally, UBS Group restated a "neutral" rating and issued a $20.00 price target (up from $18.00) on shares of AnaptysBio in a research note on Tuesday, August 12th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $48.75.

AnaptysBio Stock Down 2.0%

ANAB opened at $31.34 on Friday. AnaptysBio has a 12-month low of $12.21 and a 12-month high of $36.54. The business has a 50 day moving average of $22.34 and a 200-day moving average of $21.74. The stock has a market cap of $877.52 million, a price-to-earnings ratio of -7.00 and a beta of -0.18.

AnaptysBio (NASDAQ:ANAB - Get Free Report) last issued its earnings results on Wednesday, August 6th. The biotechnology company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.50) by $0.16. The company had revenue of $22.26 million for the quarter, compared to analysts' expectations of $11.55 million. AnaptysBio had a negative net margin of 107.66% and a negative return on equity of 366.98%.

Institutional Investors Weigh In On AnaptysBio

A number of hedge funds have recently made changes to their positions in ANAB. US Bancorp DE increased its holdings in shares of AnaptysBio by 126.5% during the first quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company's stock worth $33,000 after buying an additional 979 shares in the last quarter. Farther Finance Advisors LLC increased its stake in shares of AnaptysBio by 9,778.9% in the first quarter. Farther Finance Advisors LLC now owns 1,877 shares of the biotechnology company's stock valued at $35,000 after buying an additional 1,858 shares during the period. Tower Research Capital LLC TRC raised its holdings in AnaptysBio by 175.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company's stock valued at $48,000 after buying an additional 1,377 shares during the last quarter. Osaic Holdings Inc. boosted its position in AnaptysBio by 11,630.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company's stock worth $52,000 after buying an additional 2,326 shares during the period. Finally, GAMMA Investing LLC bought a new stake in AnaptysBio during the 1st quarter worth approximately $113,000.

About AnaptysBio

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.